Despite employer costs continuing to rise and MMA’s opposition to the legislation, which would mandate cost parity for chemotherapy treatments and limit copays to $100, the Senate voted 36-1 in favor of Senate Bill 492.
The bill would interfere with private contracts and increase the cost of employer-sponsored health care, while doing nothing to address the high cost of these drugs.
“This legislation simply shifts the cost of these drugs to the premium that the purchaser pays, whether it’s a business or an individual,” said Delaney McKinley, MMA senior director of government affairs and membership, during her prior committee testimony. “Michiganders already have guaranteed access to both oral and intravenous chemotherapy drugs while federal law sets forth requirements to ensure that these treatments are affordable for patients.”
SB 492 was referred to the House Insurance Committee. MMA will continue to oppose passage of this costly, uncompetitive legislation.
This article was published in the 10/23/17 edition of MFG Voice.